Royalty Pharma Q3 Portfolio Receipts +11% to $814M; raises FY guidance to $3,200-$3,250M

Royalty Pharma plc

2025-Q3 EPS reported $1.28 revenue$1,756,203,000

Portfolio Receipts $814M (+11% YoY); Royalty Receipts $811M (+11%). Net cash ops $703M.
Raised FY 2025 guidance: Portfolio Receipts now $3,200-$3,250M (14-16% growth, previously $3,050-$3,150M).
Adjusted EBITDA $779M, Portfolio Cash Flow $657M. Capital Deployment $1.0B in Q3 (Imdelltra, obexelimab, Amvuttra).
Repurchased 4M shares for $152M in Q3; $1.2B YTD share repurchases.
Issued $2B senior notes at 5.16% in Sep; repaid $1B notes in Aug; total debt $9.2B at 3.75% avg cost.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.